Cholera, a disease that has been around for centuries, continues to spread rapidly across 32 countries, claiming over 6,800 lives this year alone. The last major outbreak in Britain occurred in 1866, and in the US since 1911. Despite being a waterborne disease that can be easily prevented with access to safe drinking water and sanitation, it thrives in areas plagued by conflict, poverty, and inequality.
The root cause of cholera's persistence is not a lack of scientific knowledge or effective solutions, but rather a failure of leaders to act with the urgency and commitment required to tackle this crisis. A consortium of over 50 partners, led by the World Health Organization (WHO), has established the Global Task Force on Cholera Control to provide essential supplies, detect, prevent, and treat cholera outbreaks.
To combat these outbreaks, the WHO and Africa Centres for Disease Control and Prevention have launched a continental cholera emergency response plan. The disease is caused by a bacterium ingested through contaminated food or water, and can be prevented with effective vaccines. However, vaccine development has been hindered due to limited market opportunities in developing countries.
Currently, there is only one manufacturer producing cholera vaccines at the scale needed for mass vaccination campaigns: EUBiologics based in South Korea. The WHO's global cholera vaccine stockpile has distributed almost 255 million doses of vaccine to 34 countries since its establishment in 2013. However, production cannot keep up with demand, and the stockpile is regularly below the recommended threshold.
To stretch supplies further, the International Coordinating Group on Vaccine Provision (ICG) suspended the standard two-dose vaccination regimen in favour of a single dose. While this temporary solution provides protection, it wanes faster than a two-dose regimen. The demand for vaccines shows no sign of abating, and supply must increase.
In recent months, several countries have signed memoranda of understanding to establish cholera vaccine-production facilities on the continent. Zambia has partnered with China's Jijia Medical Technology Company to set up a facility in Lusaka. While expanding vaccine production is essential, it's only a short-term solution. The only long-term solution lies in investing in safe drinking water and sanitation.
Cholera is not an insurmountable medical challenge; it can be stopped. However, its persistence is largely due to the persistent issues of poverty, inequality, conflict, and displacement. To truly eradicate this disease, fundamental changes must be made by governments and leaders to address these underlying factors.
The root cause of cholera's persistence is not a lack of scientific knowledge or effective solutions, but rather a failure of leaders to act with the urgency and commitment required to tackle this crisis. A consortium of over 50 partners, led by the World Health Organization (WHO), has established the Global Task Force on Cholera Control to provide essential supplies, detect, prevent, and treat cholera outbreaks.
To combat these outbreaks, the WHO and Africa Centres for Disease Control and Prevention have launched a continental cholera emergency response plan. The disease is caused by a bacterium ingested through contaminated food or water, and can be prevented with effective vaccines. However, vaccine development has been hindered due to limited market opportunities in developing countries.
Currently, there is only one manufacturer producing cholera vaccines at the scale needed for mass vaccination campaigns: EUBiologics based in South Korea. The WHO's global cholera vaccine stockpile has distributed almost 255 million doses of vaccine to 34 countries since its establishment in 2013. However, production cannot keep up with demand, and the stockpile is regularly below the recommended threshold.
To stretch supplies further, the International Coordinating Group on Vaccine Provision (ICG) suspended the standard two-dose vaccination regimen in favour of a single dose. While this temporary solution provides protection, it wanes faster than a two-dose regimen. The demand for vaccines shows no sign of abating, and supply must increase.
In recent months, several countries have signed memoranda of understanding to establish cholera vaccine-production facilities on the continent. Zambia has partnered with China's Jijia Medical Technology Company to set up a facility in Lusaka. While expanding vaccine production is essential, it's only a short-term solution. The only long-term solution lies in investing in safe drinking water and sanitation.
Cholera is not an insurmountable medical challenge; it can be stopped. However, its persistence is largely due to the persistent issues of poverty, inequality, conflict, and displacement. To truly eradicate this disease, fundamental changes must be made by governments and leaders to address these underlying factors.